Abstract: Emergent resistance was associated with the raltegravir group (OR 2.47, 95% CI 1.02-5.99; p=0.05), baseline log10 viral load (1.83, 1.12-2.97; p=0.02), and absence of the Lys65Arg (K65R) or Lys70Glu (K70E) mutation at baseline (3.18, 1.12-9.02; p=0.03).
HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.
Result: The 22 cases experiencing virologic failure presented with the following DRMs: M46I, F53LY, I54LTV, G73ST, L76V, V82AT, I84V, I185V, N88D, and L90M for PIs; L100I, K103NS, V179F Y181C, G190AS, V106A, K103N, and P225H for NNRTIs; and
Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China.
Discussion: Results from the HIV-1 drug resistance mutation research by the International AIDS Society-USA (updated in March 2013) have revealed that PI resistance mutation sites are L10I, K20M, V32I, M36I, M46I/L, I47V/A, I50V, Q58E, A71V, G73S, V82A/F/T, I84V, L89V,L90M; NRTIs resistance mutations are M41L, A62V, PMID: 24629078
2014
BMC bioinformatics
Result: Of the 14 mutations, only L63A and H69Y were found in drug resistance positions, and T12A/I, I15V, E35D, N37D/E, R57K, K70E and I72V were contiguous to positions associated with resistance.
Result: The codons T12, N37, L63, H69, K70 and I72 include mutations weakly associated with PI resistance (T12A/I, N37D/E, L63A, H69Y, K70E, and I72R), and mutations lacking evidence of PI resist
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
PMID: 24740633
2014
The Journal of infectious diseases
Result: Of the seroconverters randomized to FTC/TDF, none showed minor variant mutations above the BCO at K65R or K70E.
Figure: DNA amplicons spanning TDF-associated mutations K65R, K70E, and FTC-associated mutations M184V/I are generated by nested RT-PCR from plasma HIV-1 virions, representing the predominant and minor quasispecies.
Figure: The number of mutation sites ineligible for testing based on preestablished criteria regarding cure primer 3' end match with viral target sequence among the 131 samples possible are as follows: K65R: n = 2 (1.5%); K70E: n = 11 (8.4%); M184V: n = 5 (3.8%); and M184I: n = 4 (3.0%).
Discussion:
Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase.
Abstract: K70R is part of the thymidine analog mutations, but also other amino acid changes have been associated with NRTI resistance, such as K70E and K70G.
[Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].
Abstract: Detected mutations were as follows: M41L, K70E, M184V, L210W and T215C/D/S, responsible for nucleoside RT inhibitor (NRTI) resistance; K103N/S and Y181C, responsible for non-nucleoside RT inhibitor (NNRTI) resistance; M46L and L90M, responsible for protease inhibitor (PI) resistance.
Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
PMID: 23443042
2013
Journal of the International AIDS Society
Result: One patient had D67DN and K70KE mutations in the proviral sequence.
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
PMID: 23687292
2013
The Journal of infectious diseases
Abstract: RESULTS: Mutations with preferential zidovudine activity, K65R or K70E, occurred in 5.3% of individuals.
HIV mutation literature information.
PMID: 
2015
The lancet. HIV
Browser Board
Co-occurred Entities
Filtrator
ViMRT